An Open-label Single- and Multiple-dose Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa Following i.v. Administration of One Dose of 270 Microg/kg and Three Doses of 90 Microg/kg in Patients With Haemophilia A or B With or Without Inhibitors

Trial Profile

An Open-label Single- and Multiple-dose Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa Following i.v. Administration of One Dose of 270 Microg/kg and Three Doses of 90 Microg/kg in Patients With Haemophilia A or B With or Without Inhibitors

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2014

At a glance

  • Drugs Eptacog alfa (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Pharmacodynamics
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 30 Nov 2013 New trial record
    • 22 Nov 2013 Status changed from recruiting to completed.
    • 25 Sep 2013 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top